Picture EBD Group Biotech Showcase 2024 San Francisco 650x100px
Document › Details

Servier. (8/24/17). "Press Release: WeHealth by Servier, Servier’s E-health Department, Teams Up with CardioRenal to Provide Better Support to Heart Failure Patients".

Organisations Organisation WeHealth by Servier (E-Health Dept. of Servier)
  Group Servier (Group)
  Organisation 2 CardioRenal S.A.S.
Products Product E-health
  Product 2 patient monitoring technology
Index term Index term Servier–CardioRenal: digital health, 201708– collab developm telemedicine tool to monitor heart failure patients with WeHealth by Servier
Persons Person Guez, David (Servier 201706 Head of WeHealth by Servier)
  Person 2 Bérenger, Maurice (CardioRenal SAS 201708 CEO)

A drop of blood analyzed by a telemedicine tool means that patients will soon track the development of their pathology and stay connected to their doctor for better healthcare and a more personalized treatment.

During the European Society of Cardiology annual congress to be held in Barcelona from 26 to 29 August, Servier and CardioRenal will be announcing the joint development of a telemedicine tool to monitor heart failure patients more effectively and reduce the impact of their pathology on public health expenditure.

With more than 12 million patients in Europe, heart failure is a widespread pathology with a high social impact. The re-hospitalization rate of patients is especially high (in France, nearly 50% in the six months following their first hospitalization1) with a high mortality rate, often due to inappropriate treatment (more than 44% for patients over the age of 75).

This is what prompted CardioRenal to develop a secure, internet-connected outpatients system which uses a drop of blood to measure three biomarkers: hemoglobin, potassium and creatinine. The measurements collected are immediately analyzed by an expert system and transferred in real time to the physician who can then adjust the patient’s prescription accordingly.

By increasing the frequency of patient monitoring, this new telemedicine instrument will allow treatment to be adapted to each individual case and avoid hospitalizations that are both traumatic for the patient and expensive for the healthcare system. Once the results have been validated by the physician, optimized treatment will be proposed to the patient while their personal data are kept in a connected electronic file.

The regulatory development and clinical trials for this innovative device will be carried out jointly by CardioRenal and WeHealth by Servier. It will then be marketed and promoted worldwide by WeHealth by Servier.

“Our ambitions in the long term with such a tool are to reduce the hospitalization rate by 40%. This represents on average an economy of 6 000 euros per patient per year and will reduce patient mortality while improving their quality of life”, declared Dr David Guez, Director of WeHealth by Servier.

“We are very pleased to have entered into this partnership with WeHealth by Servier because the synergies that have emerged will allow us to soon propose our telemedicine and personalized medicine solution to the many heart failure patients who do not benefit today from a treatment sufficiently adapted to their condition”, added Maurice Bérenger, CardioRenal’s CEO.

1 2011 data from Haute Autorité de Santé

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs 21,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric disease, oncology and diabetes, as well as by its activities in high-quality generic drugs.

About WeHealth by Servier

WeHealth by Servier is the Group’s exciting new eHealth department. Its goal is to deliver an effective response to emerging healthcare market demand for eHealth or connected health, with an approach centered on the patient.

WeHealth by Servier is driven by the spirit of entrepreneurship and intends to invest in innovations created in partnership with startups worldwide.

More information:

About CardioRenal

CardioRenal is a company dedicated to improving the quality of treatment for heart failure patients through the use of state-of-the art technology (expert systems, real-time diagnosis, microfluidics, etc.) combined with top medical expertise. Since its foundation, CardioRenal has been receiving financial backing from the Grand Est Region in France and FEDER.


Karine Bousseau
Servier External Communications
Tel: +33 1 5572 4021 /+33

Record changed: 2023-06-05


Picture Twist Bioscience Biopharma Solutions Our Gold Standard 650x200px

More documents for Servier (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x300px

» top